Home Healthcare Pharmaceuticals KRAS Inhibitor Market

KRAS Inhibitor Market Size, Share & Trends Analysis Report By Type (KRAS G12C Inhibitors, KRAS G12D Inhibitors, Others), By Drug (Sotorasib, Adagrasib, Fulzerasib, Garsorasib), By Disease Indication (Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Biliary Tract Cancer, Others), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Drug Stores & Retail Pharmacies) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 24, 2026 | Author: Debashree Bora | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Table Of Content

  1. Executive Summary
  2. Research Scope & Segmentation
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
  3. Market Opportunity Assessment
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
  4. Market Trends
    1. Drivers
    2. Market Warning Factors
    3. Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
  5. Market Assessment
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
  6. KRAS Inhibitor Market Size Analysis
    1. Introduction
    2. KRAS Inhibitor Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    3. KRAS Inhibitor Market Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
      1. Sotorasib
      2. Adagrasib
      3. Fulzerasib
      4. Garsorasib
    4. KRAS Inhibitor Market Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
      1. Non-small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    5. KRAS Inhibitor Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
  7. North America KRAS Inhibitor Market Size Analysis
    1. Introduction
    2. KRAS Inhibitor Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    3. KRAS Inhibitor Market Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
      1. Sotorasib
      2. Adagrasib
      3. Fulzerasib
      4. Garsorasib
    4. KRAS Inhibitor Market Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
      1. Non-small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    5. KRAS Inhibitor Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
    6. U.S.
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    7. Canada
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
  8. Europe KRAS Inhibitor Market Size Analysis
    1. Introduction
    2. KRAS Inhibitor Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    3. KRAS Inhibitor Market Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
      1. Sotorasib
      2. Adagrasib
      3. Fulzerasib
      4. Garsorasib
    4. KRAS Inhibitor Market Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
      1. Non-small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    5. KRAS Inhibitor Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
    6. U.K.
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    7. Germany
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    8. France
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    9. Spain
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    10. Italy
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    11. Russia
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    12. Nordic
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    13. Benelux
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    14. Rest of Europe
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
  9. APAC KRAS Inhibitor Market Size Analysis
    1. Introduction
    2. KRAS Inhibitor Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    3. KRAS Inhibitor Market Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
      1. Sotorasib
      2. Adagrasib
      3. Fulzerasib
      4. Garsorasib
    4. KRAS Inhibitor Market Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
      1. Non-small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    5. KRAS Inhibitor Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
    6. China
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    7. Korea
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    8. Japan
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    9. India
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    10. Australia
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    11. Taiwan
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    12. South East Asia
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    13. Rest of Asia-Pacific
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
  10. Middle East and Africa KRAS Inhibitor Market Size Analysis
    1. Introduction
    2. KRAS Inhibitor Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    3. KRAS Inhibitor Market Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
      1. Sotorasib
      2. Adagrasib
      3. Fulzerasib
      4. Garsorasib
    4. KRAS Inhibitor Market Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
      1. Non-small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    5. KRAS Inhibitor Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
    6. UAE
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    7. Turkey
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    8. Saudi Arabia
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    9. South Africa
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    10. Egypt
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    11. Nigeria
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    12. Rest of MEA
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
  11. LATAM KRAS Inhibitor Market Size Analysis
    1. Introduction
    2. KRAS Inhibitor Market Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
      1. KRAS G12C Inhibitors
      2. KRAS G12D Inhibitors
      3. Others
    3. KRAS Inhibitor Market Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
      1. Sotorasib
      2. Adagrasib
      3. Fulzerasib
      4. Garsorasib
    4. KRAS Inhibitor Market Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
      1. Non-small Cell Lung Cancer
      2. Colorectal Cancer
      3. Pancreatic Cancer
      4. Biliary Tract Cancer
      5. Others
    5. KRAS Inhibitor Market Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
      1. Hospital Pharmacies
      2. Specialty Pharmacies
      3. Drug Stores & Retail Pharmacies
    6. Brazil
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    7. Mexico
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    8. Argentina
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    9. Chile
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    10. Colombia
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
    11. Rest of LATAM
      1. Introduction
      2. Market Size & Forecast By Type 2022-2034 (USD MILLION/ Units)
        1. KRAS G12C Inhibitors
        2. KRAS G12D Inhibitors
        3. Others
      3. Market Size & Forecast By Drug 2022-2034 (USD MILLION/ Units)
        1. Sotorasib
        2. Adagrasib
        3. Fulzerasib
        4. Garsorasib
      4. Market Size & Forecast By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Non-small Cell Lung Cancer
        2. Colorectal Cancer
        3. Pancreatic Cancer
        4. Biliary Tract Cancer
        5. Others
      5. Market Size & Forecast By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacies
        2. Specialty Pharmacies
        3. Drug Stores & Retail Pharmacies
  12. Competitive Landscape
    1. KRAS Inhibitor Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    3. Tier Structure Analysis
    4. Recent Developments
  13. Market Players Assessment
    1. Amgen Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Bristol Myers Squibb (US)
    3. Innovent (China)
    4. InventisBio Co. Ltd. (China)
    5. Lilly (US)
    6. Hoffmann-La Roche Ltd. (Switzerland)
    7. Novartis AG (Switzerland)
    8. Merck & Co. Inc. (US)
    9. Astellas Pharma (Japan)
    10. Jacobio Pharmaceuticals (China)
  14. Research Methodology
    1. Research Data
      1. Secondary Data
        1. Major Secondary Sources
        2. Key Data from Secondary Sources
      2. Primary Data
        1. Key Data from Primary Sources
        2. Breakdown of Primaries
      3. Secondary And Primary Research
        1. Key Industry Insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
  15. Appendix
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  16. Disclaimer
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.